Galectin Therapeutics (GALT) Retained Earnings (2010 - 2026)

Galectin Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$437.6 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 247.53% year-over-year to -$437.6 million in Q1 2026; TTM through Mar 2026 was -$437.6 million, a 247.53% decrease from a year earlier, with the FY2025 full-year figure at -$432.5 million, down 246.02% from the prior year.
• Retained Earnings eased to -$437.6 million in Q1 2026 per GALT's latest filing, from -$432.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $301.1 million in Q3 2025 and bottomed at -$437.6 million in Q1 2026.
• The 5-year median for Retained Earnings is -$298.9 million (2022), against an average of -$57.6 million.
• Across the five-year window, Retained Earnings soared 185.61% in 2024 and tumbled 247.53% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$309.6 million in 2022, then declined by 14.47% to -$354.4 million in 2023, then soared by 183.59% to $296.2 million in 2024, then sank by 246.02% to -$432.5 million in 2025, then slipped by 1.17% to -$437.6 million in 2026.
• Per Business Quant, the three latest GALT Retained Earnings figures stand at -$437.6 million (Q1 2026), -$432.5 million (Q4 2025), and $301.1 million (Q3 2025).